Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROT-001 Phase 1 First-in-Human Study in Healthy Volunteers
NCT06981299Phase 1Completed
- Sponsor
- Protego Biopharma
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PROT-001 (5 arms), sponsored by Protego Biopharma. Primary endpoints: Adverse Events at 7 weeks, Systolic Blood Pressure at 7 weeks and 8 more. Started May 2025; status: completed.
02
Drugs
PROT-001
Beyond the preview
Go deeper on NCT06981299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981299.